Creating a comparable scoring system for breast cancer, which might include the evaluation of CST7 and miR-4793-5p expression, has the potential to offer significant understanding regarding the effectiveness of immunotherapy and the prediction of prognosis. The gene discussed is CST7; the disease is breast cancer.